Terms: = Endocrine gland cancer AND MUC1, PEM, 4582, ENSG00000185499, PUM, MAM6, EMA, CD227, H23AG AND Clinical Outcome
10 results:
1. Baseline immunity predicts prognosis of pancreatic cancer patients treated with WT1 and/or muc1 peptide-loaded dendritic cell vaccination and a standard chemotherapy.
Ota S; Miyashita M; Yamagishi Y; Ogasawara M
Hum Vaccin Immunother; 2021 Dec; 17(12):5563-5572. PubMed ID: 34919493
[TBL] [Abstract] [Full Text] [Related]
2. Dendritic cell vaccination combined with a conventional chemotherapy for patients with relapsed or advanced pancreatic ductal adenocarcinoma: a single-center phase I/II trial.
Ogasawara M; Miyashita M; Yamagishi Y; Ota S
Ther Apher Dial; 2021 Aug; 25(4):415-424. PubMed ID: 33886156
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic Significance of MUC-1 in Circulating Tumor Cells in Patients With Metastatic Pancreatic Adenocarcinoma.
Dotan E; Alpaugh RK; Ruth K; Negin BP; Denlinger CS; Hall MJ; Astsaturov I; McAleer C; Fittipaldi P; Thrash-Bingham C; Meropol NJ; Cohen SJ
Pancreas; 2016 Sep; 45(8):1131-5. PubMed ID: 26967453
[TBL] [Abstract] [Full Text] [Related]
4. Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: clinical and immunological data of a phase I/II clinical trial.
Antonilli M; Rahimi H; Visconti V; Napoletano C; Ruscito I; Zizzari IG; Caponnetto S; Barchiesi G; Iadarola R; Pierelli L; Rughetti A; Bellati F; Panici PB; Nuti M
Int J Oncol; 2016 Apr; 48(4):1369-78. PubMed ID: 26892612
[TBL] [Abstract] [Full Text] [Related]
5. Pathohistological subtype predicts survival in patients with intraductal papillary mucinous neoplasm (IPMN) of the pancreas.
Distler M; Kersting S; Niedergethmann M; Aust DE; Franz M; Rückert F; Ehehalt F; Pilarsky C; Post S; Saeger HD; Grützmann R
Ann Surg; 2013 Aug; 258(2):324-30. PubMed ID: 23532107
[TBL] [Abstract] [Full Text] [Related]
6. Glycodelin A is a prognostic marker to predict poor outcome in advanced stage ovarian cancer patients.
Scholz C; Heublein S; Lenhard M; Friese K; Mayr D; Jeschke U
BMC Res Notes; 2012 Oct; 5():551. PubMed ID: 23036050
[TBL] [Abstract] [Full Text] [Related]
7. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
Tothill RW; Tinker AV; George J; Brown R; Fox SB; Lade S; Johnson DS; Trivett MK; Etemadmoghadam D; Locandro B; Traficante N; Fereday S; Hung JA; Chiew YE; Haviv I; ; Gertig D; DeFazio A; Bowtell DD
Clin Cancer Res; 2008 Aug; 14(16):5198-208. PubMed ID: 18698038
[TBL] [Abstract] [Full Text] [Related]
8. Mucin gene expression in intraductal papillary-mucinous pancreatic tumours and related lesions.
Terris B; Dubois S; Buisine MP; Sauvanet A; Ruszniewski P; Aubert JP; Porchet N; Couvelard A; Degott C; Fléjou JF
J Pathol; 2002 Aug; 197(5):632-7. PubMed ID: 12210083
[TBL] [Abstract] [Full Text] [Related]
9. New classification of pancreatic intraductal papillary-mucinous tumour by mucin expression: its relationship with potential for malignancy.
Nakamura A; Horinouchi M; Goto M; Nagata K; Sakoda K; Takao S; Imai K; Kim YS; Sato E; Yonezawa S
J Pathol; 2002 Jun; 197(2):201-10. PubMed ID: 12015744
[TBL] [Abstract] [Full Text] [Related]
10. Enhancement of metastatic properties of pancreatic cancer cells by muc1 gene encoding an anti-adhesion molecule.
Satoh S; Hinoda Y; Hayashi T; Burdick MD; Imai K; Hollingsworth MA
Int J Cancer; 2000 Nov; 88(4):507-18. PubMed ID: 11058865
[TBL] [Abstract] [Full Text] [Related]
